WASHINGTON (REUTERS) - Johnson & Johnson said on Tuesday (Oct 5) it had submitted data to the US Food and Drug Administration (FDA) for emergency use authorisation of a booster shot of its Covid-19 vaccine in people aged 18 and older.
J&J said its submission includes data from a late-stage study in the United States that found a booster given 56 days after the primary dose provided 94 per cent protection against symptomatic Covid-19 and 100 per cent protection against severe disease, at least 14 days after the booster shot.
While scientists are divided over the need for booster shots when so many people in the US and other countries remain unvaccinated, the Biden administration announced the push for an extra dose in August to shore up protection against the highly transmissible Delta variant.
J&J's filing comes after the FDA last week scheduled an Oct 15 meeting of its expert advisory committee to discuss whether to authorise a second shot of the company's single-dose vaccine.
Shares of the healthcare conglomerate rose nearly 1 per cent in trading before the opening bell.
The FDA has already authorised a booster dose of the vaccine developed by Pfizer and partner BioNTech for 65-year olds and older, people at high risk of severe disease and others who are regularly exposed to the virus.
Pfizer had also asked the FDA to expand its vaccine approval to include boosters for all people aged 16 and older, but the regulator decided to limit their use, saying evidence showed they were helpful to older people and those at high risk.
Rival vaccine maker Moderna also submitted an application seeking authorisation for a booster shot of its two-dose vaccine last month, and an FDA panel will hold a meeting on Oct 14 to discuss the extra dose.
J&J said it plans to submit the data to other regulators, the World Health Organisation and National Immunisation Technical Advisory Groups to inform decision-making on local vaccine administration strategies, as needed.
About 15 million Americans aged 18 and older have received one dose of J&J's vaccine, according to latest data from the Centers for Disease Control and Prevention.